Abstract
Atrial fibrillation (AF) is the most common arrythmia in patients with cancer and management includes antiarrhythmic drugs (AAD) as well as catheter ablation (CA). There is a high risk of drug interactions in this patient population and long-term efficacy of AAD is not well defined. Catheter ablation (CA) is a well-established and safe treatment option in healthy patients with symptomatic and AAD resistant AF. However, literature regarding safety of CA for AF in patients with cancer is limited and confined to single centers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
